Most preclinical assets have no value due to their early and risky nature. The VC community and microcap healthcare world is full of hundreds of phase I/preclinical opportunities that can be acquired for nominal equity value.
Not this company. Do you really think it's special or a transitory value established by spurious means? I'm voting on the latter until I see a CFO, a Board of Directors, a Nasdaq listing, an IND, a major institutional shareholder. Heck, I'll take just one of those. Otherwise I can buy 10 companies for the price of one. Why would I bother with NNVC?
News 
Market Data 
Discover 
AI
